Alopecia

Latest News

May 1st 2024

Several Barriers Linked to Hindered Access of JAKi Therapy in Patients, Particularly Non-White, With Alopecia Areata

By Cameron Santoro

These challenges may exacerbate racial inequities in care access and quality, according to a new study.

April 5th 2024

Countdown to RAVE!

By Lois Levine, Correspondent

March 22nd 2024

COVID-19 Impacts on Hair Loss, Pemphigus, Urticaria, and Rare Diseases

By Lauren Buchanan, MA, Managing Editor

March 18th 2024

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

By Cameron Santoro

March 12th 2024

What’s New in Hair Loss Therapies and Exosomes?

By Kaitlyn Bader, Senior Editor , Ronda Farah, MD

CME Content

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Register now!

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Pointers With Portela: Hair Loss Q&A

ByDustin Portela, DO

March 6th 2024

In this week’s Pointers With Portela, the 208SkinDoc answers common hair loss questions.

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

ByEmma Andrus, Associate Editor

March 5th 2024

The study will evaluate rezpegaldesleukin and its effect on Severity of Alopecia Tool scoring by the conclusion of a 36-week period.

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

ByCameron Santoro

March 4th 2024

Factors including disease duration, treatment response, and mental health were listed as crucial factors in severity and treatment.

Alopecia

Latest News

CME Content

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Pointers With Portela: Hair Loss Q&A

Nektar Announces Initiation of Phase 2b Study for Rezpegaldesleukin in Severe, Very Severe Alopecia

Experts Review Key Factors in Alopecia Areata Severity and Morbidity Index, Treatment Decisions

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect